Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.

Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B.

Br J Dermatol. 2017 Dec;177(6):1537-1551. doi: 10.1111/bjd.15723. Epub 2017 Nov 16.

PMID:
28600810
2.

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.

Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungberg A, Acharya N, Reich K.

J Am Acad Dermatol. 2017 Mar;76(3):432-440.e17. doi: 10.1016/j.jaad.2016.09.026. Epub 2016 Nov 23.

3.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group.

Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.

4.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group.

N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8.

5.

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.

Genovese MC, Braun DK, Erickson JS, Berclaz PY, Banerjee S, Heffernan MP, Carlier H.

J Rheumatol. 2016 Feb;43(2):289-97. doi: 10.3899/jrheum.140831. Epub 2015 Dec 15.

PMID:
26669919
6.

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators.

Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10.

PMID:
26072109
7.

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.

Wenten M, Gaebler JA, Hussein M, Pelletier EM, Smith DB, Girase P, Noel RA, Braun DK, Bloomgren GL.

Diabet Med. 2012 Nov;29(11):1412-8. doi: 10.1111/j.1464-5491.2012.03652.x.

8.

A cohort study of acute pancreatitis in relation to exenatide use.

Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD.

Diabetes Obes Metab. 2011 Jun;13(6):559-66. doi: 10.1111/j.1463-1326.2011.01376.x.

PMID:
21320263
9.

The effect of exenatide re-exposure on safety and efficacy.

Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK.

Peptides. 2009 Sep;30(9):1771-4. doi: 10.1016/j.peptides.2009.06.026. Epub 2009 Jul 1.

PMID:
19576255
10.

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study.

Noel RA, Braun DK, Patterson RE, Bloomgren GL.

Diabetes Care. 2009 May;32(5):834-8. doi: 10.2337/dc08-1755. Epub 2009 Feb 10.

11.

Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results.

Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL.

Eur J Nucl Med. 1998 Sep;25(9):1238-43.

12.

Human herpesvirus 6.

Braun DK, Dominguez G, Pellett PE.

Clin Microbiol Rev. 1997 Jul;10(3):521-67. Review.

13.

Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance.

Nicas TI, Zeckel ML, Braun DK.

Trends Microbiol. 1997 Jun;5(6):240-9. Review.

PMID:
9211645
14.

Meningococcal endocarditis presenting as cellulitis.

Lin VH, Parekh RS, McQuillan MA, Braun DK, Markovitz DM.

Clin Infect Dis. 1995 Oct;21(4):1023-5.

PMID:
8645793
16.

Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia.

Walling DM, Clark NM, Markovitz DM, Frank TS, Braun DK, Eisenberg E, Krutchkoff DJ, Felix DH, Raab-Traub N.

J Infect Dis. 1995 May;171(5):1122-30.

PMID:
7751686
17.

Primary cutaneous Nocardia otitidiscaviarum infection: case report and review.

Clark NM, Braun DK, Pasternak A, Chenoweth CE.

Clin Infect Dis. 1995 May;20(5):1266-70. Review.

PMID:
7620008
18.

Fulminant hepatic failure secondary to herpes simplex virus hepatitis. Successful outcome after orthotopic liver transplantation.

Shanley CJ, Braun DK, Brown K, Turcotte JG, Greenson JK, Beals TF, Tiballi RN, Campbell DA Jr.

Transplantation. 1995 Jan 15;59(1):145-9. No abstract available.

PMID:
7839418
19.

Cryptococcal infection of a prosthetic dialysis fistula.

Braun DK, Janssen DA, Marcus JR, Kauffman CA.

Am J Kidney Dis. 1994 Nov;24(5):864-7. Review.

PMID:
7977331
20.

Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen.

Ross CW, Schnitzer B, Sheldon S, Braun DK, Hanson CA.

Am J Clin Pathol. 1994 Sep;102(3):310-5.

PMID:
8085554
21.

Bilateral renal parenchymal malacoplakia presenting as fever of unknown origin: case report and review.

Mitchell MA, Markovitz DM, Killen PD, Braun DK.

Clin Infect Dis. 1994 May;18(5):704-18. Review.

PMID:
7915547
22.

Chronic rubella vaccine-associated arthropathy.

Mitchell LA, Tingle AJ, Shukin R, Sangeorzan JA, McCune J, Braun DK.

Arch Intern Med. 1993 Oct 11;153(19):2268-74.

PMID:
8215730
23.
24.

S100-positive, T-cell chronic lymphoproliferative disease: an aggressive disorder of an uncommon T-cell subset.

Hanson CA, Bockenstedt PL, Schnitzer B, Fox DA, Kueck B, Braun DK.

Blood. 1991 Oct 1;78(7):1803-13.

25.

Characterization of herpes simplex virus 1 alpha proteins 0, 4, and 27 with monoclonal antibodies.

Ackermann M, Braun DK, Pereira L, Roizman B.

J Virol. 1984 Oct;52(1):108-18.

26.

Supplemental Content

Loading ...
Support Center